GlobeNewsWire
15 Jul 2026, 01:45 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
Crescent Biopharma is pricing a public offering of approximately 8.1 million ordinary shares and 526k pre-funded warrants at $14.50 per share. — Public offerings typically result in immediate share dilution for existing stockholders, often putting downward pressure on the stock price.
-0.40The offering is expected to generate gross proceeds of approximately $125.0 million for the company. — A significant cash infusion strengthens the balance sheet of a clinical-stage biotech company, providing necessary runway for R&D and clinical trials.
+0.30Underwriters have been granted a 30-day option to purchase an additional 1,293,103 ordinary shares. — The potential for further shares to enter the market creates additional overhang and potential for further dilution.
-0.10Which stocks this story touches
Continue reading
6 related stories
Search tags
The company is raising approximately $125 million in gross proceeds through a public offering to fund its clinical-stage oncology pipeline.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
GlobeNewsWire
1d ago
